Starting Material Control — Apheresis, Donor Qualification, and the CMC Sections CBER Scrutinizes

The most consequential CMC decision in an autologous cell therapy program is not the manufacturing process — it is how you define, characterize, and control the starting material that arrives in your facility before manufacturing begins.

Every downstream manufacturing parameter — activation reagent concentration, transduction efficiency, expansion kinetics, and final product yield — is contingent on the quality of the apheresis product collected from a patient who may be heavily pre-treated, lymphodepleted, or acutely ill. CBER’s Office of Therapeutic Products (OTP, formerly the Office of Tissues and Advanced Therapies) has identified starting material control as one of the most frequent sources of information requests during IND review, not because sponsors lack manufacturing sophistication, but because they systematically underestimate what the CMC framework for a patient-derived biological product must contain. The regulatory architecture governing the apheresis product is distinct from anything encountered in recombinant protein or small molecule development, and failing to recognize that distinction produces CMC packages that are structurally incomplete before the process description begins.

The Apheresis Product as Starting Material: What GMP Obligations Attach to Patient-Derived Material

The apheresis product collected from an autologous cell therapy patient is not a raw material in the conventional CMC sense. It is a regulated human cellular starting material whose collection, characterization, and disposition must satisfy both the Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/P) framework under 21 CFR Part 1271 and the biologics-specific requirements under 21 CFR Part 610, simultaneously. This dual regulatory overlay is the first structural fact that sponsors must internalize: the apheresis collection facility operates under CGTP, the receiving GMP manufacturing facility operates under CGMP, and the CMC section must document both layers with precision. When CBER reviewers examine the starting material section of an early IND, they are not simply asking where the apheresis product came from — they are auditing whether the sponsor has created a continuous, documented chain of identity, safety testing, and quality assessment from the moment the patient’s blood enters the apheresis circuit to the moment the starting material is released into the manufacturing suite.

The GMP obligations that attach at the manufacturing facility level are non-negotiable and frequently underspecified. The receiving site must have written procedures for starting material receipt, inspection, labeling verification, and quarantine pending infectious disease test results. More critically, if the apheresis product will be cryopreserved prior to manufacturing — as is the case for the majority of commercial autologous CAR-T programs — the cryopreservation step itself constitutes a manufacturing operation subject to process validation expectations, even if the product at that stage has not yet been transformed. ICH Q5D’s cell banking paradigm, while originally developed for cell lines used in biologic manufacturing, provides a conceptually useful framework for thinking about cryopreserved autologous starting material: each cryopreserved patient apheresis lot is, in functional terms, a unique single-use cell bank, and the characterization documentation generated at receipt and post-thaw constitutes the foundational quality record for that lot. A sponsor who treats apheresis receipt as a logistics event rather than a GMP manufacturing step has already lost control of the argument with CBER before the process section is written.

The operational failure pattern here is specific and recurring. A sponsor completes leukapheresis at a community apheresis center, ships the product on wet ice to the GMP facility, and upon receipt records only total nucleated cell count and visual inspection for hemolysis. No CD3+ T cell enumeration is performed, no viability assessment is documented, and the material proceeds immediately to activation. Six months later, during IND review, CBER issues an information request asking for the starting material specification, the acceptance criteria applied at receipt, and the disposition procedure for material that fails to meet those criteria. The sponsor has no written answers because no written criteria existed — the starting material was characterized only enough to begin manufacturing, not enough to make a defensible release decision.

Donor Qualification and the Regulatory Requirements for Autologous vs. Allogeneic Starting Materials

For autologous cell therapy products, donor eligibility determination under 21 CFR Part 1271.50 is technically simplified by the fact that the donor and the recipient are the same individual — autologous use is explicitly excepted, under 21 CFR 1271.90(a)(2), from the donor eligibility determination and the associated screening and testing requirements (21 CFR 1271.75, 1271.80, and 1271.85) that apply to allogeneic donors. However, this exception does not eliminate the practical case for infectious disease testing; it changes its purpose. FDA’s 2007 Guidance for Industry: Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps), together with FDA’s more recent CAR T cell product-specific guidance, reflects the expectation that testing still occurs in practice to protect manufacturing personnel and to prevent cross-contamination of other products manufactured in shared GMP spaces, even where the formal 1271 donor-eligibility requirement does not apply. The practical consequence is that a reactive infectious disease test result on an autologous apheresis product does not automatically disqualify the product from manufacture — but it triggers a mandatory set of procedural controls, segregation requirements, and documentation obligations that must be pre-specified in the CMC section. If the sponsor’s IND CMC package does not include a written procedure for handling reactive autologous starting material, CBER will issue a clinical hold.

For allogeneic cell therapy platforms — NK cell programs, MSC programs, or allogeneic CAR-T using healthy donor leukapheresis — the donor qualification requirements are substantively more demanding, and the parallels to the ICH Q5D cell banking framework become directly operational. The allogeneic donor functions as the equivalent of a master cell bank source: the leukapheresis product from a single healthy donor may be the founding material for a working cell bank that will support dozens or hundreds of patient doses. In this context, the full donor eligibility determination under 21 CFR 1271 applies without exception, including screening for relevant communicable disease agents and diseases (RCDADs) under 21 CFR 1271.75, and the specific donor testing requirements under 21 CFR 1271.80 and 1271.85, encompassing agents such as for HIV-1/2, HTLV-I/II, hepatitis B surface antigen, hepatitis B core antibody, hepatitis C antibody, and West Nile virus, among others. The allogeneic leukapheresis lot is the MCB-equivalent event in this paradigm, and CBER’s expectation is that the characterization package for the allogeneic starting material approaches the rigor applied to a biologics master cell bank under ICH Q5D, including genetic identity verification of the donor and full documentation of the apheresis procedure, collection volume, and lot-specific analytical results.

The most common EMA/CAT deficiency in this domain mirrors CBER’s: starting and raw material requirements for ATMPs, as articulated in EMA guidance, require that the dossier include a complete description of the source, collection procedure, and release criteria for each starting material — and for human cell-derived starting materials, the donor qualification documentation must be cross-referenced in the Module 3 dossier, not relegated to a clinical appendix. Sponsors who submit MAAs with donor eligibility documentation only in the clinical module consistently receive objections from the CAT rapporteur requesting CMC cross-referencing and specification-level documentation of infectious disease testing panels.

The Starting Material Specification: What Tests Are Required and Why CBER Reviews This Section Most Carefully

The starting material specification for an autologous apheresis product must address three analytically distinct requirements: identity, purity, and quality — applied to a material that is inherently variable between lots because each lot comes from a different patient. The identity requirement is satisfied by chain-of-identity documentation linking the patient identifier, the apheresis collection record, the product label, and the manufacturing batch record in an unbroken, auditable sequence. A break in this chain — even a labeling discrepancy at the point of cryopreservation — is a critical GMP deviation that can invalidate the entire manufacturing lot and constitutes one of the most serious CBER inspection findings in autologous cell therapy manufacturing. Purity, in this context, refers to the cellular composition of the starting material, and the minimum analytical package must include CD3+ T cell enumeration by flow cytometry as a direct measure of the substrate available for activation and transduction. A starting material that arrives with adequate total nucleated cell count but contains only 30% CD3+ T cells will behave fundamentally differently in activation than one with 70% CD3+ T cells at equivalent total cell numbers — and a process validated at one composition range will not be predictively applicable at the other.

Viability is the third critical parameter and the one most frequently underspecified. The CMC section must include a minimum viability threshold — typically assessed by 7-AAD or trypan blue exclusion — below which the starting material is rejected or subject to a formal quality review before manufacturing proceeds. This threshold is not arbitrary: it directly predicts activation efficiency, expansion fold-change, and the risk of a failed manufacturing run. A sponsor who cannot point CBER to a written, pre-specified minimum viability acceptance criterion for the apheresis product has not established a starting material specification — they have established a collection process with no quality gate. The specification must also define the acceptable window between apheresis collection and initiation of manufacturing, because cell viability and CD3+ T cell function degrade as a function of time and cold chain conditions, and the process description must be anchored to a specific hold-time window that the sponsor has validated or justified with supporting data.

The disposition criteria for out-of-specification starting material represent the most frequently absent element in early-stage cell therapy IND CMC packages. CBER expects to see a written procedure specifying what happens when a patient apheresis product does not meet the minimum acceptance criteria: is the product rejected and the patient re-apheresed? Is there a formal quality review process with defined criteria for conditional release? Is there a bridging protocol that allows manufacturing to proceed under enhanced monitoring with explicit documentation of the deviation? The absence of this procedure is not a minor gap — it is evidence that the sponsor has not thought through the clinical and operational consequences of starting material failure, which CBER interprets as a systemic quality system deficiency, not a paperwork omission.

Building a Starting Material Control System That Satisfies CBER and Protects Patient Safety

The XGene Cell Therapy Starting Material Control Architecture is a structured, end-to-end framework for defining, characterizing, testing, and releasing autologous cell therapy starting material from apheresis collection through cryopreservation and manufacturing initiation — designed to satisfy CBER and EMA/CAT review standards at IND and BLA stages.

Step 1 — Regulatory Layer Mapping: Identify every regulatory obligation that attaches to the apheresis product at each stage of its journey — CGTP at the collection facility under 21 CFR Part 1271, CGMP at the receiving GMP site under 21 CFR Part 210/211, and infectious disease testing obligations under 21 CFR 1271.85 and 21 CFR 610.40 — and document the handoff procedures that satisfy both regulatory frameworks simultaneously, with specific reference to which entity bears responsibility for each compliance obligation.

Step 2 — Starting Material Specification Development: Draft a written starting material specification that defines minimum acceptance criteria for total nucleated cell count, CD3+ T cell percentage by flow cytometry, cell viability by validated method, and collection-to-manufacturing hold time — with explicit numerical thresholds for each parameter and a pre-specified disposition procedure for material that falls outside those thresholds, including the criteria for conditional release, formal quality review, and patient re-apheresis.

Step 3 — Chain-of-Identity Architecture: Design and document the complete chain-of-identity system linking the patient identifier, the apheresis collection record, the product label at the collection site, the shipping manifest, the GMP facility receipt record, and the manufacturing batch record — with defined verification checkpoints at each transfer and a deviation procedure for any labeling or identity discrepancy discovered at any point in the chain.

Step 4 — Infectious Disease Testing Package Construction: Compile the complete infectious disease testing panel required for the product’s regulatory jurisdictions — including all agents required under 21 CFR 1271.85 and 610.40 for the U.S. and the EMA/CAT ATMP starting material requirements for Europe — and document the testing laboratory’s CLIA or equivalent certification, the test methods employed, and the written procedure for managing reactive results in the autologous context, including personnel protection, product segregation, and CMC documentation obligations.

The output of the XGene Cell Therapy Starting Material Control Architecture is a pre-submission starting material control dossier that maps each CFR citation, ICH Q5D principle, and EMA/CAT requirement to a specific written procedure, analytical method, acceptance criterion, or disposition record — not a gap analysis, but a submission-ready evidence package that anticipates CBER’s most frequent information requests before they are issued.

An autologous cell therapy program that reaches IND submission without a fully specified, written starting material control system is not missing a CMC section — it is missing the foundational quality infrastructure on which every downstream manufacturing decision depends. CBER’s information requests in this domain are not bureaucratic formalities; they are signals that the agency has identified a gap in the sponsor’s ability to make defensible lot-release decisions under conditions of real patient-to-patient variability. The cost of receiving a clinical hold on starting material grounds is not only a regulatory delay — it is the loss of the clinical timeline window in a patient population where disease progression does not wait for CMC remediation. Building the starting material control system before the IND is submitted is not a regulatory best practice; it is the minimum threshold for operating a credible autologous cell therapy program.

For your autologous cell therapy program, can you identify today the written acceptance criteria applied to the apheresis product before manufacturing is initiated — including minimum CD3+ cell count, viability threshold, and the documented disposition procedure when a patient apheresis product does not meet those criteria?